Literature DB >> 33509274

Requirement of splicing factor hnRNP A2B1 for tumorigenesis of melanoma stem cells.

Mengqi Chu1, Haitao Wan1, Xiaobo Zhang2.   

Abstract

BACKGROUND: Cancer stem cells play essential roles in tumorigenesis, thus forming an important target for tumor therapy. The hnRNP family proteins are important splicing factors that have been found to be associated with tumor progression. However, the influence of hnRNPs on cancer stem cells has not been extensively explored.
METHODS: Quantitative real-time PCR and Western blot were used to examine gene expressions. RNA immunoprecipitation assays were conducted to identify the RNAs interacted with hnRNP A2B1. The in vivo assays were performed in nude mice.
RESULTS: In this study, the results showed that out of 19 evaluated hnRNPs, hnRNP A2B1 was significantly upregulated in melanoma stem cells compared with non-stem cells, suggesting an important role of hnRNP A2B1 in cancer stem cells. Silencing of hnRNP A2B1 triggered cell cycle arrest in G2 phase, leading to apoptosis of melanoma stem cells. The results also revealed that hnRNP A2B1 could bind to the precursor mRNAs of pro-apoptosis genes (DAPK1, SYT7, and RNF128) and anti-apoptosis genes (EIF3H, TPPP3, and DOCK2) to regulate the splicing of these 6 genes, thus promoting the expressions of anti-apoptosis genes and suppressing the expressions of pro-apoptosis genes. The in vivo data indicated that hnRNP A2B1 was required for tumorigenesis by affecting the splicing of TPPP3, DOCK2, EIF3H, RNF128, DAPK1, and SYT7, thus suppressing apoptosis of melanoma stem cells.
CONCLUSION: Our findings showed the requirement of hnRNP A2B1 for tumorigenesis, thus presenting novel molecular insights into the role of hnRNPs in cancer stem cells.

Entities:  

Keywords:  Apoptosis; Cancer stem cells; Melanoma; Tumorigenesis; hnRNP

Mesh:

Substances:

Year:  2021        PMID: 33509274      PMCID: PMC7842053          DOI: 10.1186/s13287-020-02124-5

Source DB:  PubMed          Journal:  Stem Cell Res Ther        ISSN: 1757-6512            Impact factor:   6.832


  40 in total

Review 1.  Intersections of post-transcriptional gene regulatory mechanisms with intermediary metabolism.

Authors:  Waqar Arif; Gandhar Datar; Auinash Kalsotra
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2017-01-11       Impact factor: 4.490

2.  Regulatory Expansion in Mammals of Multivalent hnRNP Assemblies that Globally Control Alternative Splicing.

Authors:  Serge Gueroussov; Robert J Weatheritt; Dave O'Hanlon; Zhen-Yuan Lin; Ashrut Narula; Anne-Claude Gingras; Benjamin J Blencowe
Journal:  Cell       Date:  2017-07-13       Impact factor: 41.582

Review 3.  Splicing factors of SR and hnRNP families as regulators of apoptosis in cancer.

Authors:  Hanna Kędzierska; Agnieszka Piekiełko-Witkowska
Journal:  Cancer Lett       Date:  2017-03-14       Impact factor: 8.679

Review 4.  Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer.

Authors:  Nidhi Jyotsana; Michael Heuser
Journal:  Expert Opin Ther Targets       Date:  2017-12-20       Impact factor: 6.902

5.  Suppression of 5' splice-sites through multiple exonic motifs by hnRNP L.

Authors:  Tiing Jen Loh; Namjeong Choi; Heegyum Moon; Ha Na Jang; Yongchao Liu; Jianhua Zhou; Xuexiu Zheng; Haihong Shen
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2017-01-22       Impact factor: 4.490

Review 6.  Post-transcriptional modifications in development and stem cells.

Authors:  Michaela Frye; Sandra Blanco
Journal:  Development       Date:  2016-11-01       Impact factor: 6.868

7.  The role of miR-100 in regulating apoptosis of breast cancer cells.

Authors:  Yi Gong; Tianliang He; Lu Yang; Geng Yang; Yulei Chen; Xiaobo Zhang
Journal:  Sci Rep       Date:  2015-07-01       Impact factor: 4.379

8.  Knockdown of hnRNP A2/B1 inhibits cell proliferation, invasion and cell cycle triggering apoptosis in cervical cancer via PI3K/AKT signaling pathway.

Authors:  Xiang Shi; Li Ran; Yao Liu; Shu-Huai Zhong; Ping-Ping Zhou; Ming-Xin Liao; Wen Fang
Journal:  Oncol Rep       Date:  2018-01-05       Impact factor: 3.906

9.  Co-regulatory activity of hnRNP K and NS1-BP in influenza and human mRNA splicing.

Authors:  Matthew G Thompson; Raquel Muñoz-Moreno; Prasanna Bhat; Renat Roytenberg; John Lindberg; Matthew R Gazzara; Michael J Mallory; Ke Zhang; Adolfo García-Sastre; Beatriz M A Fontoura; Kristen W Lynch
Journal:  Nat Commun       Date:  2018-06-19       Impact factor: 14.919

10.  Interleukin-6, -8, and TGF-β Secreted from Mesenchymal Stem Cells Show Functional Role in Reduction of Telomerase Activity of Leukemia Cell Via Wnt5a/β-Catenin and P53 Pathways.

Authors:  Ezzatollah Fathi; Behnaz Valipour; Zohreh Sanaat; Hojjatollah Nozad Charoudeh; Raheleh Farahzadi
Journal:  Adv Pharm Bull       Date:  2020-02-18
View more
  5 in total

1.  SYT7 acts as an oncogene and a potential therapeutic target and was regulated by ΔNp63α in HNSCC.

Authors:  You Fu; Guocai Tian; Zhiyuan Zhang; Xiao Yang
Journal:  Cancer Cell Int       Date:  2021-12-20       Impact factor: 5.722

2.  Celastrus orbiculatus Extract Reduces Stemness of Gastric Cancer Stem Cells by Targeting PDCD4 and EIF3H.

Authors:  Yao-Dong Zhu; He Ba; Jie Chen; Mei Zhang; Ping Li
Journal:  Integr Cancer Ther       Date:  2021 Jan-Dec       Impact factor: 3.279

3.  Modulatory Role of TPPP3 in Microtubule Organization and Its Impact on Alpha-Synuclein Pathology.

Authors:  Judit Oláh; Attila Lehotzky; Tibor Szénási; Tímea Berki; Judit Ovádi
Journal:  Cells       Date:  2022-09-27       Impact factor: 7.666

Review 4.  Insights from DOCK2 in cell function and pathophysiology.

Authors:  Lulin Ji; Shuquan Xu; Haiqing Luo; Fanwei Zeng
Journal:  Front Mol Biosci       Date:  2022-09-29

Review 5.  The Interplay between Tumour Microenvironment Components in Malignant Melanoma.

Authors:  Cornelia Amalinei; Adriana Grigoraș; Ludmila Lozneanu; Irina-Draga Căruntu; Simona-Eliza Giușcă; Raluca Anca Balan
Journal:  Medicina (Kaunas)       Date:  2022-03-02       Impact factor: 2.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.